Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma.
Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma.
复制标题
DOI：
10.3389/fonc.2018.00508
复制
发表时间：
2018
影响因子：
4.7
通讯作者：
Massaia M
中科院分区：
文献类型：
--
作者：
Castella B;Melaccio A;Foglietta M;Riganti C;Massaia M
免疫检查点（ICP）阻断的出现为癌症治疗带来了前所未有的范式转变。虽然非常有希望，但仍有相当比例的患者对ICP阻滞剂无反应或产生耐药性。迫切需要体外和体内模型来鉴定使ICP阻断的免疫效力最大化并克服对ICP阻断的原发性和获得性抗性的机制。从多发性骨髓瘤（MM）的骨髓（BM）中分离的Vγ 9VS 2 T细胞是研究对PD-1阻断的抗性机制和破译PD-1与免疫抑制性肿瘤微环境（TME）之间相互作用的网络的极好工具。可以容易地询问Vγ 9VS 2 T细胞以剖析通过长期暴露于骨髓瘤细胞在TME中产生的进行性免疫能力损伤。BM MM Vγ9Vδ2 T细胞为PD-1+，对磷酸化抗原（pAg）刺激无反应性;值得注意的是，单药PD-1阻断不足以完全恢复其体外抗肿瘤活性，表明Vγ9Vδ2 T细胞的无反应性中涉及其他参与者。在这篇简短的综述中，我们将讨论Vγ9Vδ2 T细胞作为研究工具的价值，以提高MM的ICP阻断和免疫干预的效力。
The advent of immune checkpoint (ICP) blockade has introduced an unprecedented paradigm shift in the treatment of cancer. Though very promising, there is still a substantial proportion of patients who do not respond or develop resistance to ICP blockade. In vitro and in vivo models are eagerly needed to identify mechanisms to maximize the immune potency of ICP blockade and overcome primary and acquired resistance to ICP blockade. Vγ9Vδ2 T cells isolated from the bone marrow (BM) from multiple myeloma (MM) are excellent tools to investigate the mechanisms of resistance to PD-1 blockade and to decipher the network of mutual interactions between PD-1 and the immune suppressive tumor microenvironment (TME). Vγ9Vδ2 T cells can easily be interrogated to dissect the progressive immune competence impairment generated in the TME by the long-lasting exposure to myeloma cellss. BM MM Vγ9Vδ2 T cells are PD-1+ and anergic to phosphoantigen (pAg) stimulation; notably, single agent PD-1 blockade is insufficient to fully recover their anti-tumor activity in vitro indicating that additional players are involved in the anergy of Vγ9Vδ2 T cells. In this mini-review we will discuss the value of Vγ9Vδ2 T cells as investigational tools to improve the potency of ICP blockade and immune interventions in MM.
登录
查看更多内容
影响因子：
10.1
作者：
Chung DJ;Pronschinske KB;Shyer JA;Sharma S;Leung S;Curran SA;Lesokhin AM;Devlin SM;Giralt SA;Young JW
通讯作者：
Young JW
影响因子：
7.2
作者：
Calcinotto, Arianna;Ponzoni, Maurilio;Bellone, Matteo
通讯作者：
Bellone, Matteo
DOI：
10.1073/pnas.0810059106
发表时间：
2009-02-17
影响因子：
11.1
作者：
Brandes, Marlene;Willimann, Katharina;Moser, Bernhard
通讯作者：
Moser, Bernhard
影响因子：
12.4
作者：
Deniger, Drew C.;Switzer, Kirsten;Cooper, Laurence J. N.
通讯作者：
Cooper, Laurence J. N.
DOI：
10.1016/j.beha.2018.03.002
发表时间：
2018-06
期刊：
Best practice & research. Clinical haematology
影响因子：
--
作者：
Danhof S;Hudecek M;Smith EL
通讯作者：
Smith EL